Can Pharmaceutical Pricing Move Beyond Cost/QALY for Value Consideration?
Author(s)
Moderator: Omar Dabbous, MD, MPH, Novartis Gene Therapies, Inc., Bannockburn, IL, USA
Speakers: Michael Drummond, MCom, DPhil, Centre for Health Economics, University of York, York, UK; Sean D Sullivan, BScPharm, PhD, University of Washington, Seattle, WA, USA
Current economic evaluation studies may underestimate the value of innovative cell and gene therapies in rare diseases, impacting on Health Technology Assessment (HTA) frameworks, market access and pricing decisions. This symposium will explore additional add-on benefits of gene therapies apart from quality-adjusted life years (QALYs) that may be considered, how these can be quantified, and their role in influencing economic modelling. Using case studies of value assessment frameworks, panelists will discuss the value of pricing factors beyond cost and QALY considerations for gene therapies.
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Code
211
Topic
Economic Evaluation